LO LOESTRIN FE REQUEST SAMPLES
 

Lo Loestrin® Fe is committed to providing helpful resources for your practice and your patients:

 

Request samples

To request your samples of Lo Loestrin Fe, please print out the Sample Request fax-back form and fax the completed form to 1.866.765.7098 or request online.

DOWNLOAD SAMPLE REQUEST FORM
 

Dispense as Written (DAW)

Remember to include Dispense as Written (DAW) on prescriptions, so your patients receive branded Lo Loestrin Fe at the pharmacy.

 

The Lo Loestrin® Fe Savings Program

With the Lo Loestrin Fe Savings Card, eligible patients may pay as little as $25* for a 1-month or 3-month prescription fill. Consider writing a 3-month prescription for fewer trips to the pharmacy.

* Depending on insurance coverage, eligible patients may pay as little as $25 for each of up to 13 one-month Lo Loestrin® Fe prescription fills OR each of up to 4 three-month Lo Loestrin® Fe prescription fills. Check with pharmacist for copay discount. Maximum savings limits apply; patient out-of-pocket expense will vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see Program Terms, Conditions, and Eligibility Criteria on back of card or click here.

Eligible patients can access the Lo Loestrin Fe Savings Card in the 3 following ways:

 

Getting her started

The Lo Loestrin® Fe Patient Brochure and Setting Expectations Patient Sheet may help patients get off to a good start with Lo Loestrin Fe. The brochure also helps patients understand their pill pack and have access to the Lo Loestrin Fe Savings Program. Use the Sample Request fax-back form to request more patient support materials.

DOWNLOAD PATIENT BROCHUREDOWNLOAD PATIENT SHEET
 
 
INDICATIONS AND USAGE

Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of >35 kg/m2 has not been evaluated.

IMPORTANT SAFETY INFORMATION

Warning: cigarette smoking and serious cardiovascular events Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.

Contraindications

Lo Loestrin Fe is contraindicated in pregnant patients, in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Warnings and Precautions

Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are pre-diabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.

Adverse Reactions

In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.

Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Please see full Prescribing Information, including Boxed Warning, for Lo Loestrin Fe.

 
REFERENCES

1. IQVIA™. Monthly New Rx by Specialty; February 2017-January 2018 (claim derived from the use of information under under license from IQVIA, expressly reserves all rights, including rights of copying, distribution, and republication). 2. Lo Loestrin® Fe prescribing information. Irvine, CA: Allergan USA, Inc.; 2017. 3. Data on file. Allergan USA, Inc.: Madison, NJ. 4. Managed Markets Insight and Technology, LLC™, a trademark of MMIT. Database as of September 2018. Data are subject to change. 5. Data on file. Allergan USA, Inc.: Madison, NJ. 6. The Alan Guttmacher Institute. Fulfilling the promise: public policy and U.S. family planning clinics. http://www.guttmacher.org/pubs/fulfill.pdf. Accessed January 31, 2018. 7. Ortho Tri-Cyclen® Lo prescribing information. Titusville, NJ: Janssen Pharmaceuticals; 2009. 8. Archer OF, Nakajima ST, Sawyer AT, et al. Obstet Gynecol. 2013;122(3):601-607. 9. Ogden CL, Carroll MD, Kit BK, Flegal KM. JAMA. 2014;311 (8):806-814. 10. Nakajima ST, Archer DF, Ellman H. Contraception. 2007;75(1):16-22. 11. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Contraception. 2006;74(2):100-103. 12. Spona J, Elstein M, Feichtinger W, et al. Contraception. 1996;54(2):71-77.

IMPORTANT SAFETY INFORMATION More Less

Warning: cigarette smoking and serious cardiovascular events Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.

Contraindications

Lo Loestrin Fe is contraindicated in pregnant patients, in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Warnings and Precautions

Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are pre-diabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.

Adverse Reactions

In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression.

Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Please see full Prescribing Information, including Boxed Warning, for Lo Loestrin Fe.